Medincell Publishes its Consolidated Half-Year Financial Results (April 1st , 2025 – September 30, 2025)
December 9, 2025
December 9, 2025
Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-‘749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults
December 9, 2025
December 9, 2025
Videoconference and publication of half-year financial results, Tuesday, December 9, 2025
December 1, 2025
December 1, 2025
Medincell Management to Present at the 8th Annual Evercore Healthcare Conference and at the Piper Sandler 37th Annual Healthcare Conference
November 27, 2025
November 27, 2025
Medincell Awarded New Grant to Fight Malaria
November 24, 2025
November 24, 2025
[Replay] Jefferies Global Healthcare Conference 2025
November 13, 2025
November 13, 2025
Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth
November 11, 2025
November 11, 2025
Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark
November 10, 2025
November 10, 2025
Medincell to Participate in the UBS Global Healthcare Conference (Palm Beach) and the Stifel Healthcare Conference (New-York)
November 6, 2025
November 6, 2025
UZEDY® continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025
November 5, 2025
November 5, 2025
Medincell to Participate in the 2025 Truist Securities Biopharma Symposium (New-York)
October 22, 2025
October 22, 2025
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
October 10, 2025
October 10, 2025
Contacts
Medincell
David Heuzé
Head of Corporate and Financial Communications, and ESG
